Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb Co said on Friday its blockbuster cancer drug Opdivo failed to meet the main goal in patients with a type of lung cancer, that had relapsed after chemotherapy. FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018.

from Biotech News